Amarin Corp Plc (AMRN)

[HinduKush]

The antibody test to SARS-CoV2 is an IgG (delayed Ig response) test...NO one has categorically established in an US study group the indicence or persistence of seroconversion status after an acute proven SAR-CoV2 infection episode. Moreover, there are documented cases of proven infection where the individuals have mounted a TRANSIENT positive serological rise to return to low (negative) levels thereafter--the significance of which is also unknown. There is not even any information that scientifically validates this serological rise as being protective immunologically.In light of the disputed efficacy of plasma (antibody included) transfusions in recovered COVID survivors...this leave sthe whole field in acurrent cloud of scientific uncertainty..
HK

https://www.hematology.org/covid-19/covid-19-and-convalescent-plasma

Here is a good article:
https://www.nejm.org/doi/full/10.1056/NEJMc2025179

The protective role of antibodies against SARS-CoV-2 is unknown, but these antibodies are usually a reasonable correlate of antiviral immunity, and anti–receptor-binding domain antibody levels correspond to plasma viral neutralizing activity. Given that early antibody decay after acute viral antigenic exposure is approximately exponential,3 we found antibody loss that was quicker than that reported for SARS-CoV-1,4,5 and our findings were more consistent with those of Long et al.1 Our findings raise concern that humoral immunity against SARS-CoV-2 may not be long lasting in persons with mild illness, who compose the majority of persons with Covid-19. It is difficult to extrapolate beyond our observation period of approximately 90 days because it is likely that the decay will decelerate.3 Still, the results call for caution regarding antibody-based “immunity passports,” herd immunity, and perhaps vaccine durability, especially in light of short-lived immunity against common human coronaviruses. Further studies will be needed to define a quantitative protection threshold and rate of decline of antiviral antibodies beyond 90 days.

Prevalence varies even across the united States as expected by SARS-CoV2 infection rates and herd immunity...
https://jamanetwork.com/journals/jama/fullarticle/2769322

A 13.7% prevalence of SARS-CoV-2 antibodies in this large cohort study of HCP in the greater NYC area was similar to that among adults randomly tested in New York State (14.0%)4 but higher than among adults in Los Angeles (4.1%).5 HCP in a single hospital in Belgium had lower seroprevalence (6.4%), which was significantly associated only with household contact.6 In this study, high levels of HCP-reported suspicion of virus exposure and prior positive PCR testing results were most strongly associated with seropositivity.